BioPharmSignal logoBioPharmSignal

Biotech News

Charles River Laboratories Announces First-Quarter 2026 Results

Charles River (CRL)Charles RiverEarnings

– Reports First-Quarter Revenue of $995.8 Million, GAAP Loss per Share of $(0.30), and Non-GAAP Earnings per Share of $2.06 – – Reaffirms 2026 Guidance for Organic Revenue and Non-GAAP Earnings per Share – – Repurchased $200 Million of Common Stock in First Quarter of 2026 – – Completed the

Related news

CRLCharles River2026-04-16 12:00 EST

Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call

CRLCharles River2026-08-05 11:00 EST

Charles River Laboratories Announces Second-Quarter 2026 Results

View all latest news

Charles River

Preclinical Research Services Charles River Laboratories provides products and outsourced services used by pharmaceutical, biotechnology, academic and government researchers across early drug development. Research Models and Services The company supplies research models and related services used in basic research, target validation and...

Recent company news

CRLCharles River2026-08-05 11:00 EST

Charles River Laboratories Announces Second-Quarter 2026 Results

CRLCharles River2026-07-15 12:00 EST

Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call

CRLCharles River2026-07-13 12:00 EST

Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches

CRLCharles River2026-06-18 12:00 EST

Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise

CRLCharles River2026-06-01 12:00 EST

Charles River Laboratories to Present at William Blair and Jefferies Conferences

Stock data

Close
265.51 USD
Market cap
8.42B USD
Exchange
NYSE
Sector
Biopharma
Location
United States